Bionano Genomics (NASDAQ: BNGO – Get Rating) and Standard BioTools (NASDAQ: LAB – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.
This table compares Bionano Genomics and Standard BioTools’ net margins, return on equity and return on assets.
|Net Margins:||Return on Equity:||Return on Assets:|
Valuation & Earnings:
This table compares Bionano Genomics and Standard BioTools’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue:||Price / Sales Ratio:||Net Income:||Earnings Per Share:||Price / Earnings Ratio:|
|Bionano Genomics:||$ 17.98 million:||24.33:||– $ 72.43 million:||($ 0.33)||-4.58:|
|Standard BioTools:||$ 130.58 million:||1.06:||– $ 59.24 million:||($ 1.52)||-1.18:|
Standard BioTools has higher revenue and earnings than Bionano Genomics. Bionano Genomics is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the most affordable of the two stocks.
This is a summary of recent ratings and target prices for Bionano Genomics and Standard BioTools, as reported by MarketBeat.com.
|Sell Ratings:||Hold Ratings:||Buy Ratings:||Strong Buy Ratings:||Rating Score:|
|Standard BioTools:||0:||0:||0:||0:||N / A:|
Bionano Genomics presently has a consensus price target of $ 11.00, indicating a potential upside of 628.48%. Given Bionano Genomics’ higher probable upside, research analysts plainly believe Bionano Genomics is more favorable than Standard BioTools.
Risk and Volatility:
Bionano Genomics has a beta of 2.16, meaning that its stock price is 116% more volatile than the S&P 500. Comparatively, Standard BioTools has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500.
Insider and Institutional Ownership:
26.4% of Bionano Genomics shares are owned by institutional investors. 1.2% of Bionano Genomics shares are owned by insiders. Comparatively, 2.9% of Standard BioTools shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Bionano Genomics beats Standard BioTools on 7 of the 13 factors compared between the two stocks.
About Bionano Genomics: (Get Rating)
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, an exome sequencing test to identify genetic variants that are associated with childhood development disorders; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
About Standard BioTools: (Get Rating)
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Receive News & Ratings for Bionano Genomics Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bionano Genomics and related companies with MarketBeat.com’s FREE daily email newsletter.